Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-317-7 | CAS number: 119-36-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Carcinogenicity
Administrative data
Description of key information
No full carcinogenicity study according to current guidelines is available. Assessment of the carcinogenic potential of MeS has been made based on chronic studies on MeS itself, plus a screening carcinogenicity study on SA and data on carcinogenic potential of sodium salicylate (NaS) and Acetylsalicylic acid (ASA).
Key value for chemical safety assessment
Carcinogenicity: via oral route
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 50 mg/kg bw/day
Justification for classification or non-classification
Not carcinogenic according to EU and GHS (UN/EU) criteria.
Based on chronic toxicity studies in rats and dogs and on absence of carcinogenicity in a screening study on SA.
Additional information
The evaluation of the carcinogenic potential of MeS was included in 2 -year studies on the chronic toxicity of MeS by the oral route in rats and dogs (Webb and Hansen, 1963). In the rat, at 0, 0.1%, 0.5%, 1.0% or 2.0% MeS in diet, the only tumors described were pituitary tumours. Similar incidences of benign pituitary tumours were reported in controls and treated rats. Malignant pituitary tumours were reported in 3 rats at 0.5% but none at 1% MeS in diet. No tumors were reported in dogs fed MeS in capsule form at doses of 0, 50, 150 or 350 mg/kg/bw/day for 2 years.
In a non-standard carcinogenicity study (Stoner et al., 1973), MeS was tested by the intraperitoneal route in the A/He strain of mouse, a strain susceptible to carcinogen-induced lung tumorigenesis. In the low-dose group, 2/15 (13%) males and 1/15 (6%) females developed lung tumors while in the high-dose group, 1/15 males (6%) and 5/15 (33%) females developed lung tumors. In comparison, 22/80 (28%) male and 16/80 (20%) female control mice developed "spontaneous" lung tumors. MeS was reported as negative for pulmonary tumour response in this assay.
In Chang et al. (1983), the cocarcinogenic potential of acetylsalicylic acid on gastric tumors induced by N-Nitroso-N-methylnitroguanidine in rats was studied. No gastro-intestinal tumors were found with rats treated only with acetylsalicylic acid twice a week for 18 months.
In a screening test for carcinogenic hazard of SA (Uhmeda. 1957), rats were fed with salicylic acid or injected with sodium salicylate in solution. None of the animals treated with salicylic acid developed tumors in any organ in the course of the experiment. No marked change in internal organs was found in the rats treated with sodium salicylate under the conditions of this experiment.
MeS has been studied for anti-carcinogenic potential in several older assays (Strong, 1932 and Boyland and Huntsman-Mawson, 1938). A number of epidemiological studies have claimed that low doses of aspirin (ASA) are effective in preventing colorectal cancer. The most detailed scientific evaluation on the efficacy of aspirin (ASA) as a colorectal cancer chemopreventive has been conducted by a Working Group of experts convened by the International Agency for Research on Cancer (IARC). This Working Group (IARC, 1997) considered that the strength of scientific evidence that aspirin prevents colorectal cancer in humans was limited.[p1]
Taken together, the data on these salicylates suggest that salicylic acid would have no carcinogenic potential.
[p1]IARC Handbooks of Cancer Prevention. Volume 1 - Non-steroidal anti-inflammatory drugs. International Agency for Research on Cancer, , 1997.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.